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Introduction: Reduced concentrations of placental protein 13 (PP13) during the first trimes-
ter of human pregnancy are associated with elevated risk for the subsequent development of 
preeclampsia, which is one of the deadliest obstetrical complications of pregnancy. Previous 
studies by our group have shown that PP13 lowers blood pressure in pregnant rats, increases the 
size and weight of pups and placentas, and induces vasodilation of resistance arteries through 
endothelial signaling pathways involving endothelial nitric oxid synthase and prostaglandin. 
Methods: In the present study, the effect of PP13 was investigated in nonpregnant female 
Sprague Dawley rats (n=27). Osmotic pumps were surgically implanted subcutaneously that 
released a constant dose of PP13 or saline over 7 days. Most animals were sacrificed 6 days 
after the end of PP13 release (on day 13), while some were sacrificed immediately at the end 
of day 7 (the last PP13 release day), to compare the short- and long-term impact of PP13 on 
vessels’ growth and size. 
Results: The uterine vessels were significantly expanded in the group exposed to recombinant 
PP13 (rPP13) compared to the control (saline) group. Both veins and arteries were significantly 
expanded by rPP13 with a more pronounced effect after 13 days compared to the correspond-
ing vessels after 7 days. Furthermore, the long-term effect of treatment by rPP13 was more 
pronounced in the veins compared to the corresponding arteries. The effect of a PP13 variant 
with a histidine-tag (His-PP13) remained the same between 7 and 13 days. 
Conclusion: In conclusion, PP13 might play a key role in the expansive remodeling of the 
uterine vessels, reflecting what would happen if the rat was pregnant, preparing the uterine vascu-
lature for the increase in uteroplacental blood flow, which is necessary for normal pregnancy. We 
suggest that PP13 could act by NO signaling pathways, a hypothesis that requires future study.
Keywords: preeclampsia, placenta, biomarkers, LGALS13, hypertension, pregnancy, rat 
vascular system, galectins, eNOS, slow release
Introduction
During mammalian pregnancy, the uterine circulation undergoes significant remodeling 
to enable an increased blood flow, which is necessary for the development and outcome 
of a healthy pregnancy.1 The structural adaptation of the uteroplacental vasculature in 
pregnancy is reflected by a reduced systemic and uterine vascular resistance, especially 
during the first trimester, to ensure the appropriate blood supply for a successful fetal 
growth.2
Placental protein 13 (PP13) was identified as a strong modifier for uterine vasculature 
expansion in a pregnant rat model.3 PP13 is a member of the placenta-specific galectins 
(LGALS13) that is found only in human beings and some primates (anthropoid apes).4 
Like all the galectins, it binds to various glycoproteins and glycolipids through their 
sugar residues, eg, on the outer surface of the placental syncytiotrophoblast. It also binds 
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to sugar residues of white blood cells through its carbohydrate 
recognition domain (CRD), creating a carbohydrate tethering 
effect.4 This pattern of galectin binding is thus considered to 
occur via a nonclassical receptor entity. A recent study has 
identified PP13 on the surface and within the placental syncy-
tiotrophoblast-derived extracellular vesicles (both exosomes 
and microvesicles) that deliver their content to the maternal 
circulation.5 Several studies have reported that low PP13 levels 
in the first trimester of human pregnancy may be associated 
with an increased risk for the subsequent development of 
preeclampsia, which is a life-threatening pregnancy complica-
tion occurring in 2%–5% of all pregnancies worldwide that is 
characterized by a new onset of hypertension and proteinuria 
from the midst of pregnancy in previously non-symptomatic 
women.6,7 PP13 was identified as a possible biomarker for 
predicting this pregnancy complication that is associated 
with a failure of the maternal vascular system to undergo the 
required changes to accommodate pregnancy. Accordingly, 
the shortage of PP13 during the early stages of pregnancy 
may be related to impaired vascular adaptation to pregnancy.
Our team has previously shown that a slow continuous 
release of PP13 into the subcutaneous area in pregnant rats 
induces hypotension and dilation of the uterine vasculature. 
When PP13 is allowed to flow through isolated arteries from 
pregnant and nonpregnant rats, it induces dilation of these 
resistance arteries through endothelial signaling involving the 
pathways of endothelial nitric oxid synthase (eNOS) and prosta-
glandin.3,8 PP13 is also implied in venous dilation, and the closer 
the veins are to the placenta, the greater effect was observed.3
The purpose of this study was to evaluate whether the 
effect of PP13 on uterine blood vessels is related to their 
distance from the uterine endometrium. Specifically, we 
were interested to 1) study in vivo effects of PP13 on the 
uterine vascular system as a whole and compare its effect on 
uterine veins and arteries; 2) evaluate the type of the most 
affected uterine vessels comparing resistance (small) vessels 
to conductive (large) vessels; and 3) assess whether the PP13 
effect lasts longer than the administration of the protein. The 
analysis took into consideration presence of PP13 in blood is 
between 6 and 12 hours following a single injection, although 
binding of PP13 to body tissues, including white and the red 
blood cells, as well as ABO antigen system may extend the 
time PP13 may be found in the circulation.9,10
Materials and methods
PP13
Recombinant PP13 (rPP13) was made using two variants of 
the PP13 with (His-PP13) and without (rPP13) histidine tag. 
The His-tag was localized at the N-terminus of the PP13 
primary sequence. Both variants were cloned and expressed 
in Escherichia coli. The rPP13 was harvested from the inclu-
sion bodies and solubilized and refolded in the presence of 
urea, cysteine, and protease inhibitors. The refolded protein 
was subsequently purified by ion exchange chromatography 
as previously described.11
The His-PP13 variant was initially purified by NiNTA 
affinity purification followed by ion exchange chromatog-
raphy as previously described.12
The molecular weight and the purity of the proteins were 
determined by SDS-PAGE (15.6 and 18.2 kDa for rPP13 
and His-PP13, respectively), and the purity was verified by 
HPLC and immunoblots with PP13-specific monoclonal 
antibodies. The concentration was determined using a PP13 
ELISA kit as previously described.12–14
animals and ethical approvals
The animal experiments were approved by the National 
Laboratory Review Board of Iceland (no 2015-02-01) and by 
the Institutional Animal Care and Use Committee (IACUC) 
at the University of Vermont, Burlington, VT, USA. All 
studies were carried out in accordance with the European 
Communities Council Directive (86/609/EEC) or the US 
National Institutes of Health (NIH) Guidelines for the care 
and use of laboratory animals. All efforts were undertaken 
according to the “3R principles” (www.nc3rs.org.uk) to 
reduce the number of animals used in this study and optimize 
experimental protocols for obtaining maximum data from 
each tested animal. Part of the experiments (13 day study) 
was carried out at an authorized animal facility at ArticLAS 
ehf (Reykjavik, Iceland), and part of them (the 7-day study) 
was carried out at the College of Medicine, University of 
Vermont, Burlington, VT, USA.
We used two groups of animals: 1) 18 female nonpreg-
nant Sprague Dawley rats (aged 11 weeks) were purchased 
from Taconic bioscience (Ejby, Denmark) and studied in 
Iceland; 2) 11 female nonpregnant Sprague Dawley rats (aged 
12–14 weeks) were purchased from Charles River Laborato-
ries (St Constant, QC, Canada) and studied in Vermont. The 
animals were acclimatized for 3–14 days prior to the start of 
the experiments. Food and water were provided ad libitum, 
and animals were kept under 12/12-hour light/dark cycle.
Drug administration and osmotic pump 
implantation
All animals were subcutaneously surgically implanted with 
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The slow release osmotic mini-pumps (Alzet, Model 2 
ML1) with 2 mL capacity were loaded with 127 ng of rPP13 
(n=10) or of His-PP13 (n=8), releasing 10 µL/h or 0.625 ng 
protein/h and emptying their content over 7 days. The dosage 
chosen corresponds to the concentration of the protein in mater-
nal blood in the first trimester of pregnancy.5 Control animals 
received similar osmotic pumps filled with saline solution (n=9).
The short-term study consisted of three treatment groups 
with three to four animals per group. The animals were eutha-
nized 7 days after surgery (active protein effect). The long-term 
study consisted of six animals per group, of which two of the 
His-tag PP13 group died during the pump implantation surgery. 
Animals were euthanized 13 days after the pump implantation 
surgery (extended effect). The 13-day timing was chosen to 
mimic the study performed in pregnant rats, in which the osmotic 
pump implantation took place at day 8 of pregnancy (trophoblast 
invasion time in rats15), and rats were sacrificed at day 21.
Diameter evaluation of vessels
extended protein effect (13 days)
All rat uteri were dissected, one uterine horn was photo-
graphed on a petri dish and the other was placed into buffered 
formalin solution for 48 hours, and then transferred to PBS 
pH 7.4. Formalin-fixed parts of the uterine horns were paraffin 
embedded and sliced to 4 µm thick sections before staining. 
The sections were stained by H&E dye and visualized and 
analyzed using Nanozoomer Digital Pathology software.
To determine the vessel type, first vessels in the uterine 
mesometrium were measured (main uterine vein [MUV], main 
uterine artery [MUA], and arcuate vessels [arcuate uterine 
artery and vein {AUA and AUV, respectively}]; Figure 1A), 
and then myometrial vessels (radial uterine vein and artery 
[RUV and RUA, respectively]) were assessed (Figure 1B). 
Vessel sizes were analyzed using GraphPad Prism 
(GraphPad Software, Inc., La Jolla, CA, USA) that calculated 
the area of each vessel’s lumen and converted it to vessel 





where D is the diameter and A is the area.
Altogether, the analysis included for each animal was as 
follows: 2–3 MUAs and MUVs, 10–15 AUVs and AUAs, and 
15–25 RUAs and RUVs, depending on the size of the sample.
active protein effect (7 days)
All fresh uteri were pinned in petri dishes that were filled 
with relaxing solution (10 mM HEPES saline at 4°C contain-
ing 100 µM papaverine and 1 µM diltiazem mixture). All 
vessel diameters were measured directly through a calibrated 
stereomicroscope (Carl Zeiss Meditec AG, Jena, Germany) 
to evaluate vascular diameter between groups. In this group, 
MUVs and MUAs were measured on both uterine horns of 
each animal at three sites, the ovarian end, in the middle of the 
uterine horn and at the cervical end (n=24, n=24, and n=18, 
for the PP13, His-PP13, and the saline groups, respectively; 
Table 1). The radial and smaller uterine arteries and veins 
were not included in this analysis since they were too small 
for the resolution of the stereomicroscope.
statistical analyses
The data groups were compared by Mann–Whitney test to 
evaluate the significance of differences between the study 
groups: rPP13, His-PP13, and saline solution (control).16 
All values listed in Tables 1 and 2 are reported as mean ± SD, 
with p-values ,0.05 considered significant.
Figure 1 (A) cross sections of the uterus showing the veins (v) and arteries (a) within the mesometrium stained with H&e. corresponding to the two uterine horns there 
are two main utero-ovarian arteries and veins that are positioned in the mesometrium parallel to each uterine horn. arcuate vessels run from the main vessels and form 
loops that are also positioned in the mesometrium. (B) At the same magnification, a cross section through the uterus provides a view on a fraction of the uterus showing the 
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There were no differences among the nonpregnant animal 
groups in terms of weight gain or blood pressure. The latter was 
different from previous studies in pregnant rats, where blood 
pressure was reduced during the active stage of PP13 release.10
Vascular expansion
Images of the effect of PP13 on the vascular system of the 
uterine horns of three representative animals are depicted 
at 13 days (eg, consisted of 7 days of active PP13 release 
and the following 6 days) as shown in Figure 2. The clear 
expansion of the uterine vessels in the rPP13 group (Figure 2, 
bottom) is depicted compared to the His-PP13 (middle) and 
the saline solution (top) groups.
short-term vascular expansion (7 days)
After 7 days of active release of rPP13, His-PP13, and saline 
solution, there was a significant expansion of the MUAs 
and MUVs and of the RUVs by rPP13 compared to saline 
solution (Table 1). The table also depicts a tendency toward 
vessel expansion by His-PP13, but the effect was significant 
only on the RUVs.
long-term vascular expansion (13 days)
Veins
The analysis of uterine vein diameters for the main vein 
(MUV; Figure 3A, p,0.05), arcuate vein (AUV; Figure 3B, 
p,0.01), and RUV (Figure 3C, p,0.01) revealed that expo-
sure to rPP13 is accompanied with a significant dilation of 
all three venous types compared to the saline solution, as 
Table 1 Vessel diameters measured after 7 days
Type of 
vessels




































Notes: Diameters of uterine veins and arteries from nonpregnant rats treated with 
rPP13, His-PP13, or saline solution (control) released for 7 days from subcutaneous 
pumps. The values in brackets show the ratio of size increase compared to the 
control. Data are reported as mean ± sD. n is the number of vessels. small letters 
right to the numbers are the Mann–Whitney values for the direction of significant 
differences between the vessels of the same type among the treatment groups.16 
aSignificantly higher than all other groups. bSignificantly lower than a but significantly 
higher than control group.
Abbreviations: MUa, main uterine artery; MUV, main uterine vein; rUV, radial 
uterine vein.
Table 2 Vessel diameter measured after 13 days





































































Notes: Diameters of nonpregnant rat uterine veins (top part) and arteries (bottom part) treated with rPP13, His-PP13, or the control saline group, measured 13 days after 
pump insertion (ie, 6 days post 7 days of active pump release). The values in brackets show the ratio of size increase compared to the control group. Data are reported as 
mean ± SD. N is the number of vessels. The superscript letters are Mann–Whitney indication for the direction of the significant differences for vessels of the same type among 
the treatment groups: asignificantly higher than all other groups; bsignificantly higher thanc, but significantly lower thana; csignificantly lower than all groups.16 *A significant 
difference (p,0.05) of the same vessel’s types between 13 days (this table) compared to 7 days (Table 1).
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summarized in Table 2. The vessels of the His-PP13 group 
also showed significant expansion of the MUV, but not of 
the AUV and RUV (Table 2 [veins]).
arteries
The analysis of diameter change was performed on the main 
(MUA; Figure 4A), arcuate (AUA; Figure 4B), and radial 
(RUA; Figure 4C) arteries. It revealed that there was no 
significant expansion of the MUA caused by either rPP13 or 
His-PP13 (Table 2 [arteries]). However, a significant differ-
ence was observed in both AUA and RUA (p,0.05) for the 
rPP13 treated group, compared to the saline solution (Table 2 
[arteries]). In contrast, there were no significant changes in 
uterine arteries following His-PP13 administration, compared 
to controls (Table 2 [arteries]).
comparison of long- and short-term 
effects
The long- and short-term effects of the PP13 variants on the 
vessel diameters were compared between the tested time 
points (7 and 13 days).
The comparison of rPP13 effects on the MUV showed 
that the venous diameter further increased from the end of 
protein release (7 days) to 6 days later (p=0.0159), while 
there was no further significant expansion for His-PP13 
(p=0.6857).
The diameter of the RUVs and of the MUA did 
not further change between 7 and 13 days, keeping the 
differences between the groups unchanged (compare 
Tables 1 and 2).
Figure 2 Uterine horns freshly dissected from non-pregnant rats at 13 days (six days 
after seven-day exposure to reagent release from the inserted osmotic pumps). Top: 
saline treated animal; middle: His-PP13 treated animal; bottom: rPP13 treated animal.
Figure 3 long-term effects of rPP13 and His-PP13 on the diameters of uterine 
veins: MUV, aUV, and rUV. Data are reported as median ± IQr.
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This study revealed the expansion of the uterine arteries and 
veins at various levels in nonpregnant rats. The analysis of 
the uterine arteries and veins was carried out immediately 
at the end of the PP13 release at days 7 and 13 (6 days after 
the pumps were emptied of their PP13 content). The major 
findings of this study are as follows: 1) rPP13 dilates both 
the uterine arteries and veins during the active polypeptide 
release (7 days) and also at 6 days after the pumps were empty 
(13 days group). The polypeptide effect appears greater in 
the extended time group (ie, a larger extension by rPP13 at 
13 days compared to 7 days). 2) His-PP13 was found to be 
an effective short-term vasodilator of both arteries and veins, 
but its long-term effect is limited. 3) For the veins – the 
larger the vein (MUV) the greater was the long-term dilation 
effect. Arterial dilation appears to behave in the opposite 
direction – with a larger extension of the radial arteries than 
the extension of the arcuate arteries and MUAs after 13 days.
Maternal uterine vascular adaptations in pregnancy are 
among the most important physiological events occurring 
during pregnancy to enable the increase in blood flow to 
supply sufficient oxygen and nutrients to the fetal–placental 
unit. If altered or impaired, it might trigger complications 
related to placental insufficiency such as in the early-onset 
preeclampsia and fetal growth restriction. Previous studies 
have shown that PP13 can be detected in the maternal circula-
tion of human pregnancies from the 5th week of gestation. 
Thus, it is reasonable to hypothesize that PP13 may have a 
role in vascular remodeling of uterine vessels in a very early 
stage right from the beginning of pregnancy.17
The expansion of uterine arteries and veins by PP13 has 
to be evaluated in the context of the uterine vascular changes 
during pregnancy. During human pregnancy, cardiac output 
and maternal blood volume increase by approximately 40% 
and heart rate increases by approximately 30%. Uterine 
vascular remodeling is part of a large vascular change that 
takes place in pregnancy, where the circulatory blood flow 
directed through the uterus increases significantly, and 
the vascular resistance drops significantly, resulting in the 
decrease in blood pressure.18,19 In experimental animals such 
as rats, the changes in uteroplacental blood flow during 
pregnancy are greater than in human beings, reaching almost 
a 70-fold increase, compared to the nonpregnant state.2,20 
In this respect, the significant arterial and venous expansion 
in nonpregnant rats by PP13 appears to be an important 
component that explains the physiological adaptation of the 
vascular system during pregnancy.
In the past, the major research emphasis was on arterial 
remodeling, their expansion by the migrating trophoblasts 
causing the expansion and remodeling of the spiral arteries in 
human pregnancy. A much lower attention was given to the 
remodeling of the vein that is necessary to complete the circle 
of blood flow through the uterus during pregnancy. However, 
more recent studies have pointed out that both the uterine 
arteries and the veins undergo changes and remodeling dur-
ing pregnancy21,22 to allow for the increase in uterine blood 
flow. Yet, the changes in the venous side of the circulation 
Figure 4 long-term effects of rPP13 and His-PP13 on the diameters of uterine 
arteries: MUa, aUa, and rUa. Data are reported as median ± IQr.
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are much less investigated. Gyselaers et al23,24 showed in 
a series of studies that venous hemodynamic changes in 
several organs during gestation and that the failure of such 
changes are associated with pregnancy complications such 
as preeclampsia.23,24 Interestingly, the vasodilating effect of 
PP13 measured in this study suggests that PP13 is a potent 
mediator not only of the arteries but also of venous expansion.
Our findings emphasize the involvement of PP13, 
a placenta-specific galectin, expressed by the placental 
syncytiotrophoblast, in uterine blood vessel remodeling in 
pregnancy. In addition, previous studies have shown that 
PP13 turns the decidua immune tolerant to the invading 
trophoblast during pregnancy.4,25 Kliman et al25 showed 
strong PP13 staining around small uterine veins. In that 
study, performed in sections of women placentas during the 
first trimester after social termination, the presence of PP13 
around the veins was discussed in the context of rendering 
the decidua immune tolerant to the migrating trophoblasts. 
The vein accumulation of PP13 was proposed to cause a 
divergence of the immune response away from the arteries 
to allow spiral arteries remodeling by the migrating tropho-
blasts, thereby enabling the deep placentation.4,25–27 In the 
current study, we discovered the very strong direct effect of 
PP13 on uterine venous expansion. Therefore, PP13 appears 
to have a dual effect: immunologically, it turns the decidua 
immune tolerant to the pregnancy, and physiologically it 
remodels both arteries and veins thus increasing blood flow to 
the pregnancy and contributing to the major vascular changes 
in pregnancy. Thus, this study suggests that the shortage of 
PP13 in the first trimester may lead to impaired vascular 
remodeling by a lack of vessel expansion and increased 
immune rejection in pregnancy.
Studies performed in the third trimester of pregnancy 
have shown an increased release of necrotic vesicles from 
the villous trophoblast into the maternal blood, bringing 
large amounts of PP13 to the circulation near the time of 
the outbreak of hypertension in preeclampsia and during 
the development of all other clinical symptoms.17 Dys-
regulated villous trophoblast differentiation contributes to 
elevated PP13 release at the time of clinical symptoms of 
preeclampsia. The role of such elevated levels of PP13 at 
the time of the pathology is not fully explored. In view of 
the effect of PP13 on arterial and venous expansion that 
was identified in this study, a third trimester increase in 
maternal blood PP13 may be interpreted as a body rescue 
mechanism to fight hypertension by enhancing vasodilation 
to decrease peripheral resistance.3,17 This assumption war-
rants further studies.
In our previous in vitro studies on isolated rat arteries, 
we demonstrated that the endothelial layer of the arteries in 
both pregnant and nonpregnant rats is mediating the PP13 
effects. The PP13-induced vasodilation of the resistance 
arteries involves the endothelium-derived relaxing factors, 
eNOS and prostaglandins.8 In addition, to the former in vivo 
findings in pregnant rats, we have demonstrated arterial 
expansion caused by PP13.3 Here, we did a thorough quan-
titative comparison of arterial and venous expansion in vivo 
in nonpregnant rats. It emphasizes that the underlying PP13-
associated vascular expansion is general and not dependent 
on pregnancy.
The comparison of the long-term PP13 effects on arteries 
and veins revealed a much larger (double) expansion of 
veins by 39%–86%, compared to a lower expansion of 
the corresponding arteries by 19%–46%, showing that the 
uterine vessel dilation effect associated with pregnancy is 
higher in veins than in arteries. A thorough in vitro analysis 
of the PP13 effect on isolated veins is now conducted by 
our group. The different vasodilation effects of PP13 on 
arteries and veins as was determined in this study could be 
the result of: 1) a relative difference in the time and amount 
of PP13 they are exposed to (small veins are most potent 
in absorbing polypeptides from the inter-peritoneal flow 
compared to arteries), and thus PP13 that was absorbed by 
the veins might be further diluted; 2) arteries and veins may 
have different sensitivity to PP13. Although the polypeptide 
does not have a known “receptor” in the classical definition, 
it is acting through the eNOS and prostaglandin 2 pathways, 
and the density of these systems may be different between 
arteries and veins. Additional in vitro studies may shed light 
on this aspect.
Our study also shows the central role of veins in the 
circulating blood volume changes. The blood return to the 
heart is regulated by venous reflex-induced constriction and 
creates negative pressure gradients in the circulation. This 
is important in the case of blood volume expansion, like 
in pregnancy, where the excess blood volume is stored in 
the venous compartment.23,24,28 Our study implies that PP13 
might be a key molecule or a major signaling molecule by 
which the placenta can regulate hemodynamic changes in the 
reproductive maternal organs during pregnancy either accel-
erating blood release from the placenta through the expanded 
uterine veins and/or by increasing the supply of oxygen and 
nutrients via the expanded uterine arteries. It is interesting 
that the rat radial arteries (corresponding to human spiral 
arteries) appear to be more affected by PP13 given their much 
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required to analyze the underlying pathways involved in the 
venous expansion by PP13. However, there are some indica-
tions that the effect could be mediated by the NO signaling 
pathway. It has been found that endothelial vasodilatory 
responsiveness in pregnancy increases and that this expan-
sion appears to be primarily mediated by an NO-dependent 
mechanism.1,6,8 Interestingly, this effect appears to last for 
a prolonged time frame that could be measured 6 days after 
emptying the pumps releasing PP13.
Our group is currently conducting an additional set of 
experiments, where the impact of adding the NO inhibitor 
N-nitro-L-arginine methyl ester is tested in vivo to evaluate 
its potential impact on vasodilation following the slow release 
of PP13 from implanted pumps. Preliminary data indicated 
that indeed NO blockers could decrease the vasodilation pro-
duced by slow PP13 release in vivo, but a thorough analysis 
is still warranted.
This study examined the arterial and venous expansion 
immediately after the full release of PP13 from the sub-
cutaneous inserted pumps and 6 days after the release had 
stopped. We observed that the release of rPP13 and His-PP13 
actively expanded the diameters of both veins and arteries. 
The measured effect of rPP13 at day 7 is less for MUV, than 
6 days later, showing that the rPP13 is still working on the 
vessels, although the active polypeptide delivery had stopped. 
Therefore, it seems that in these vessels the expansion is 
primed and is continuously acting without the requirement 
of the permanent release of PP13. The extended effect may 
be derived from a very high affinity of PP13 to certain bind-
ing sites in these vessels that lasts beyond its active release. 
Alternatively, it can be attributed to the features of the 
underlying pathways, which may be independent of the active 
presence of rPP13. Our pharmacokinetic studies revealed 
that the half-life of rPP13 is 6–13 hours.10 The pharmacoki-
netic studies also indicated a slow release of low amount of 
PP13 from body tissues within 24 hours or more. Overall, 
it appears that the long-term effect measured here reflects 
a PP13-induced vasodilation that is maintained throughout 
the period of the polypeptide release from the pumps and 
beyond and primes vessels for additional structural expan-
sion that is manifested for a longer period. His-PP13, on the 
other hand, has the polyhistidine sequence attached to the 
N-terminus, which prohibits PP13 dimerization, has been 
already shown to be less stable in the body fluids, tends 
to precipitate, and becomes rapidly inactive (compared to 
rPP13 that forms stable dimers), corresponding to its lower 
and shorter lasting effects.
There are few limitations to this study: 1) the effect of 
PP13 on vessel diameter examined when sacrificed after 
7 days was conducted when the vessels were left in relaxing 
solution and reached maximum relaxation whereas at 13 days 
they were fixed after a shorter period. To compare the groups, 
the size factor between saline-treated groups was used to 
normalize the size of the groups; 2) at the end of the treat-
ment (both 7 and 13 days), the rats were euthanized without 
taking the estrous cycle phase into consideration; 3) also, 
we know that the life span of the His-PP13 (a monomer) is 
shorter than the life span of rPP13, which tends to form stable 
dimers. A previous study has shown that the rPP13 dimer (as 
well as the native PP13 in vivo) is more stable in solution, 
whereas the His-PP13 forms monomers or long oligomers 
that precipitate in solution.12 Thus, it appears reasonable to 
assume that the lower impact of His-PP13 compared to the 
rPP13 may be due to the faster removal of His-PP13 from 
blood. Interestingly, we have previously been able to show 
that a single subcutaneous application of PP13 takes over 
24 hours to be cleared from blood.10 However, an additional 
direct monitoring of the clearance of PP13 from blood after 
a continuous infusion is required. Further studies are also 
required to examine the PP13-NO pathway in veins, which 
could be implied from the current study.
Another study limitation was related to our focus on 
the uterus. A thorough analysis of the PP13 effect on other 
organs is ahead of us. It was relatively surprising that the 
vasodilation of arteries and veins in the nonpregnant animals 
was not accompanied by a reduced blood pressure. Drobnjak 
et al10 showed that the effect of PP13 on vasodilation in 
pregnant animals is much larger in the uterine vascular 
system (approximately 48% dilation) compared to mesenteric 
vessels (approximately 20% dilation). Unlike pregnant rats 
where the blood flow through the uterus accounts for 30% 
of the total blood flow, in nonpregnant rats only a very small 
fraction of the blood flows through the uterus. Thus, it may 
not contribute much to the entire systemic blood pressure 
in nonpregnant animals. Further evaluation of this point 
is required.
Conclusion
The comprehensive impact of PP13 on the uterine vascu-
lar system is shown in Figure 5. In a very early stage of 
pregnancy (week 5), PP13 is expressed by the placental 
syncytiotrophoblast in very high amount (reaching 2.5 mg in 
the term placenta). The release of PP13 dilates arteries and 
veins and thereby regulates the flow to and from the feto-
placental unit. The vasoactive effect of PP13: 1) generates 
an immediate effect on both veins and arteries; 2) generates 
a longer effect, which is subsequently developed (more 





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





Figure 5 Integrated effect of PP13 on the vascular system. a schematic description integrating the impact of PP13 on the vascular system that shows how PP13 could 
influence the vascular system and prime it to be ready for its increased role in pregnancy.
to a structural expansion of the veins and the arteries; and 
3) by redirecting the blood flow to the uterus, PP13 is able to 
secure selective growth of the fetus and the placenta. It may 
also generate a systemic effect on the maternal vasculature, 
thereby causing a reduced maternal blood pressure, at least 
during pregnancy. A potential cross talk between the arteries 
and the veins should be further investigated. Based on the 
proposed model, PP13 might be a potential candidate for the 
treatment of preeclampsia cases associated with impaired 
vascular remodeling, where the vasodilatory effect of the 
protein can overcome the lack of arterial expansion given 
the long-term effect identified here. This prolonged impact 
may be attributed to high protein affinity to the vessel walls 
that contributes to the long-term effect. Altogether, this study 
shows that PP13 may be an effective preconditioning modi-
fier of vascular remodeling of the rat uterine vasculature. Its 
effect in human beings remains to be evaluated.
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